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THROMBOTIC THROMBOCYTOPENIC PURPURA FOLLOWING BONE 
MARROW TRANSPLANT TREATMENT AND OUTCOME IN TEN 
PATIENTS 
Peres, E.M.; Abella, E.; Damey, R. Stem cell Tmmplam, K~Trmanos 
Cancer Institute, Detroit, MI. 
Severe thrombotic thrombocytopenic purpura OH'P) requiring 
intervention is a serious complication following bone marrow 
transplant (BMT). The therapeutic modalities (unlike classic T IP )  
are limited since therapeutic plasma exchange has a very poor 
response. BMT TTP is usually associated with cyclosporine, total 
body irradiation or other medications. A total of 10 patients who 
underwent BNIT were diagnosed with severe TTP  during 1996- 
2001 age range 5-58 (mean 27.2). The diagnosis was made based on 
the criteria of thrombocytopenia, microhemangiopathic emolytic 
anemia, elevated LDH mean 5012 (range 4672-9232) and schisto- 
cytes on the peripheral smear. Of the 10 patients, 2 were treated 
with plasma exchange (20%), and 9 patients were treated with sup- 
portive care and the discontinuation f cyclosporine (90%). Of the 
10 patients 9 were allogeneic bone marrow transplants 5 being 
MUD (50%) all patients except i were receiving cyclosporine at 
the time of diagnosis. Outcome: mortality was 100% in all patients 
treated with and without plasma exchange. There appears to be no 
benefit of plasma exchange in patients with severe TTP  after BMT 
and an improved understanding of the pathogens i and treatment 
of this complication is currently needed. 
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A FLUORESCENCE-BASED ASSAY SUITABLE FOR MONITORING NR 
ACTIVITY IN CLINICAL SETTINGS 
Sto~wls, R. V~I; Gree~z, P.D/; Chao, N.J/; Smitt,, C,4.2; Nikcevieh, 
D.AJ 1. Departmem of Medicim, Dzdee U~tiversity 3ledical Cemer, 
Din'ham,, NC; 2. Moffitt Cmzcer Cemer, Tampa, FL. 
Natural killer (NK) cells are increasing important within the con- 
text of cellular therapies, to include allogeneic bone marrow trans- 
plantafion and donor lymphocyte infilsions. Historically, 51Cr release 
has been the standard hz vitro measurement for NK activity. Howev- 
er, qCr release has pour sensitivity for NK activity if effector cell 
numbers are limiting and patients undergoing allogeneic transplanta- 
tion frequently have very low blood cell counts. To support our on- 
going clinical protocols in allogeneic bone marrow transplantation, 
we have developed a fluorescence-based assay to monitor NIL func- 
tion that is accurate ven with limiting effector cell numbers. In this 
assay the target cells are labeled with carbo .xyfluorescein diaeetate suc- 
cinimydyl ester (CFSE). After incubations with NK cells, the kilting 
of target cells is monitored by their membrane permeability asdetect- 
ed with the nucleic acid stain 7-amino actinomycin D (TAAD). In par- 
allel assays, the CFSE-based assay generated dose-response curves 
similar to those achieved with SlCr release assays. However, the fluo- 
rescence-based assay remained sensitive at lower target cell numbers 
where the results of 51Cr-release assays were not interpretable. As 
would be anticipated, an immtmomagnetic selection of CD56 + ceils 
greatly increased the sensitivity of the assay. More importantly, with 
CD56+-selected ceils as effectors the CFSE-based lysis assay yields 
classic sig~oidal dose-response curves in assays performed in as little 
as one hour. Finally, we note that with this combination of fluores- 
cent dyes file samples can be fixed with formaldehyde and processed 
at a later time. Taken together, these data demonstrate his fluores- 
cence-based lysis assay issensitive, asy to conduct and time effective, 
yet the materials are inexpensive, making it suitable for clinical use. 
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NMDP MARROW COLLECTION CENTER EXPERIENCE AND ITS EFFECT 
ON CELL CONCENTRATION AND CELL DOSE 
Robit~ett, Pff. l; Simm; P. I; Hemlan, ft. 2; Karanes, C.1; Kelwalz, N.A. 3; 
Lymh, ff.p.4; Pvzepiorka, D. % Ubevti, ff /; Welte, IC ~ I. NMDP, Min- 
neapolis, 3/1N," 2. Thomas Jefferson U~ziversity Hospitals, Philadelphia, 
Rk 3. 3/lemorial Sloan Ketteri~zg Career Center, New York, NY," 
4. Saint Fmmis Hospital, Tul~:a, OK; 5. University of Tennessee, Mem- 
phis, TN," 6. University of Michigan Meckbal Ceme'r, Amz Arbor, 3/11. 
As increasing numbers of unrelated onor stem cell transplants 
utilize peripheral blood stem cells (PBSC), physicians are per- 
forming fewer marrow collections. The National Marrow Donor 
Program (NMDP) evaluated ata from its collection centers to 
determine if there were differences in marrow cellularity or donor 
morbidity based on the marrow collection experience of the col- 
lection center. NMDP collection centers (n=97) were divided into 
tbur groups, based on the nmnber of NMDP marrow collections 
performed at the center in 2001. Each group performed appro~ 
mately 25% of all NMDP marrow collections (n=926) in 2001. 
Group 1 centers each performed _>24 NMDP collections, group 2 
between 16 and 23, group 3 between 8 and 15 collections, and 
group 4 performed <7 collections in 2001. The median cell dose 
(x 10S/kg recipient weight) and median nucleated ceil concentra- 
tion (x 106/ml) were compared among groups using a median test. 
There was no significant difference in the median cell dose among 
the four groups of centers, however there was a borderline signifi- 
cant difference (P-value = 0.02) among median cell concentra- 
tions, where group 2 had a slightly higher median cell concentra- 
tion than the other groups. The incidence of severe (very intense, 
prolonged or excruciating) donor post-donation complication 
rates reported by NMDP donor centers was also compared. There 
were no significant differences among groups 1, 2, 3 and 4 at 
0.5%, 1%, 2% and 2% respectively. In conclusion, NMDP data 
do not appear to indicate that collection centers with less marrow 
collection experience produce less cellular products or result in 
increased onor morbidity. 
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FACTORS ASSOCIATED WITH AMBIVALENCE ABOUT BONE MAR- 
ROW DONATION AMONG NEWLY RECRUITED UNRELATED POTEN- 
TIAL DONORS 
Switze~% G.E.; Myaskovsky, L.; Goycoolea, J.M.; Dew, ~i. Medickze, 
University of Pittsbm-gh Medical Cemer, Pittsburgh, PA. 
Our previous research indicated that feelings of ambivalence or 
reluctance about donation were associated with donors' decisions 
not to donate, and with less positive physical and psychosocial 
outcomes among donors who donated espite feeling ambivalent. 
The current study examines the prevalence of ambivalence among 
newly recruited potential bone marrow donors, and identifies fac- 
tors associated with greater ambivalence. Using a cross-sectional 
design, questionnaires were mailed to a stratified random sample 
of individuals newly recruited to the NMDP registry at 71 local 
donor centers. 426 (63%) of new recruits completed and returned 
the questionnaire. Bivariate analyses indicated that multiple 
recruimmnt experience and donor perception variables were sig- 
nificantly associated with ambivalence. Multivariate analysis 
revealed that eight variables - -  participating in other volunteer 
activities (p<.05), joining at a drive for a specific patient (p<.05), 
perceiving the recruitment s aff as less informative (p<.001), being 
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discouraged from joining by others (p<.001), not having an intrin- 
sic commitment to donate (p<.001), feeling encouraged by ones' 
culture or religion to join (p<.05), feeling like there are risks to 
donat ion (p<.01), and having a greater number  of medical 
(p<.001), and work and family concerns (p<.05) about donation - -  
were uniquely associated with higher levels of ambivalence after 
adjusting for the effects of other key indicators. We can conclude 
from these findings, that potential donors who are nmtivated by 
an intrinsic connnitment to donate, rather than extrinsic pressure, 
are less ambivalent about donating. In addition, recrnitment staff 
have a potentially critical role in reducing ambivalence among 
new recruits by providing information that may allay any unrealis- 
tic concerns recruits may have about the medical risks, and the 
impact of donation on work and family commitments. 
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T-CELL DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION 
FOLLOWED BY T CELL ADD-BACK IN PATIENTS WITH MULTIPLE 
MYELOMA 
Magalhaes-SilveJvna~l, M.; Lee, C.; Hohl, R.; Ritehie, J.; GiJzgrich, R. 
Interval MedMTze, University of Iowa, Iowa City, L~I. 
Allogeneic haematopoietic transplantation is potentially curative 
for patients (pts) with multiple myeloma. However, a high treat- 
ment-related mortality contributes to poor overall survival.An allo- 
geneic graft-versus-myeloma effect mediated by donor lymphocyte 
infusions has been demonstrated. Measures to minimize TRM while 
maintaining a graft-versus-host myeloma are needed.We valuated 
the outcome of 21 patients (pts) treated with a conditioning regimen 
comprising TBI  (1200cGY) ,  BCNU (300mg/m2), etoposide 
(1200rag/m2), ARA-C (6gin/m-') and cyclophosphamide (90mg/Kg) 
followed by T cell depleted bone marrow transplantation. Donor T 
cells were infused after transplantation ver a period of 2-3 months if 
acute GVHD gradec~ II was not seen. Cyclosporin was used for 
GVHD prophylaxis. Ten pts underwent transplantation using a sib- 
ling donor while 11 had an unrelated onor. There were 21 pts with 
a median age of 52 years (range 42-56); 14 were male and 7 female; 
median time from diagaaosis to transplantation was 16 months (range 
5-60); at diagnosis all pts had stage III disease; Ig type was igG in in 
12 pts, IgA in 5 and light chain in 4. Seventeen pts had sensitive dis- 
ease at time of transplantation. Twenty pts survived more than 21 
days and are evaluable for engraftment. The  median time to 
ANCc<0.5xl09/g was 14 days (range 12-30) and to a 
plateletc~25x10Q/L was 29 (range 12-70). Five pts died before day 
100. Cox proportional hazards models were used to identify factors 
associated with disease-free (DFS) and overall survival (OS). The risk 
factors considered : type of transplant( related vs unrelated), age ( 
<_50 vs~50), acute GVHD, chronic GVHD, disease sensitivity, gen- 
der, immunoglobulin type and T cell add-back. Univariate analysis 
demonstrated that gender (p=0.046) and T cell add-back (p=0.008) 
were predictive of OS. Type of transplant (p=0.047) and T cell add- 
back (p=0.005) were predictive of DFS. In a multivariate model type 
of transplant and T cell add-back were significantly associated with 
OS and DFS. The two year estimated OS and DFS for pts receiving 
T cell add-back is 50% and 40% respectively and for those not 
receiving T cell add-back is 9% and 0%. Our study demonstrates 
that T cell add-back after allogeneic T ceil depleted bone marrow 
transplantation induces ignificant graft-versus-myeloma effect. 
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ALLOGENEIC BONE MARROW TRANSPLANTATION FOR MYELOFIBRO- 
SIS DUE TO AGNOGENIC MYELOID METAPLASIA (AMM) AND ESSEN- 
TIAL THROMBOCYTOSIS (ET): EXPERIENCE OF TWO BONE MARROW 
TRANSPLANT CENTERS 
Daly, A.1; So~g, K.e; 3/les, mer, H.1; Liptm~, J.~; Hasegawa, ~V. ; Nevill, 
T.:; Toze, C.'-; Na*~tel, S.:; Hogge, D.2; Forrest, D."; Lavoie, j.e; 
&M)erlaud, It.2; Shepherd, ft.'-;ILiss, T5 l. Princess Margaret Hospital 
(PMH), Toronto, ON, Canada; 2. l, St*ecolmer General Hospital 
(UGH), Uan,:ozwer, BC, Cana&. 
Between August 1990 and June 2002, 25 patients with MF due 
to AMM (n=19) or ET  (n=6) underwent al loBMT at PMH or 
VGH.  The  median age at transplant was 48.7 ( Interquart i le 
range(IQR) 45.9-50.4) years, 18/25 were male and Lille risk 
groups at diagnosis were low (n=3), intermediate (n=13) and high 
(n=9) at diagnosis. Cytogenetics were abnormal in 8/19 cases test 
ed. Seven patients had previously undergone splenectomy and 
none of the patients had received induction therapy for leukemic 
transformation. Transplants took place a median of 10.7 (IQR 
5.67-26.5) months after diagnosis and median follow-up of surviv 
ing patients is 35 (IQR 21-61) months. Conditioning regimens 
were Cy/TBI (n=23) or Bu/Cy-2 (n=2), and all received CyA-Mtx 
for GVI ID  prophylaxis. Donors were matched (n=13) or mis- 
matched (n=2) relatives or matched unrelated volunteers (n=10). 
The median cell dose was 2.8 (IQR 1.88-3.78) xl0A8 MNC/kg. 
ANC > 500/btL and platelets > 20, 000/btL were observed in 22/22 
(median 25d.) and 17/22 (median 35d.) evaluable patients, respec- 
tively; median time to last RBC transfusion was 123 day's. Prior 
splenectomy was associated with more rapid neutrophil recovery 
(20 vs. 27.5 days, p=0.0019). Primary graft failure occurred in two 
cases, but both patients successfi~lly engrafted with a second trans- 
plant. Hepatic VOD occurred in 10 cases. Acute GVHD was 
grade II-IV in 13 and III IV in 4 cases. Chronic GVHD occurred 
in 10/17 evaluable patients. Eighteen patients had at least one 
bone marrow biopsy after transplantation. Median time to free- 
dora from fibrosis was 363d; at 18 months 84% of patients were 
free of fibrosis. A complete remission (defined as normalization of 
blood counts and absence of fibrosis and splenomegaly) occurred 
in 6 and CRP(as for CR with platelet count below normal) in 2 of 
18 cases with repeat biopsies. Median survival was 13.1 (IQR 3.6- 
33.8) months from BMT, 49.8 (IQR 17-66) months from diagno- 
sis. Kaplan-Meier estimate of 18-month overall survival was 
48.4%. Secondary engraftment failure occurred in one patient 
who died of GVHD on day 109. Non-re lapse mortal ity was 
observed in 10 cases and 4 patients died of progressive disease. We 
conclude that alloBMT offers a reasonable chance for resolution 
of MF, and may result in long-term disease-free survival. 
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THE OTTAWA IO-YEAR EXPERIENCE IN ALLOGENEIC STEM CELL 
TRANSPLANTATION FOR FOLLICULAR LYMPHOMA 
Sal, lofl~ M.S ; 3/lcDiar'mid, S/ ; Be~zce-Bruckler, I /  ; Atkins, H.2; Bredes- 
ou, C.s; Hopkins, H.Z; Genest, P.~-; Pe*'vy, G.2; Huebsch, b.lg. 1 
1. Ottawa Hospital, Ottawa, ON, CaTlada; 2. Ottawa Regio*~al Ca*lcer 
Cemre, Ottawa, ON, Canada, 3. Medical College of ~/iscousin, Mil- 
waukee, ~1~7. 
Allogeneic hematopoietic stem cell transplants (al lo-HSCT) 
have a number  of potent ia l  advantages over an autologous 
henaatopoietic stem cell transplant (AHSCT) in the treatment of 
follicular lymphoma (FL). We analyzed our experience in allo- 
HSCT for FL after establishing a program at our institution, 10 
years ago. Between April 1992 and September 1999, 19 patients 
with FL underwent an allo-HSCT. The median age was 41.7 (29- 
55) years. 8/19 were male. The  original diagnosis was FSCL 
(10/19), FML (4/19), FLCL (2/19) and 3/19 were transformed. 
5/10 had a previous AHSCT.  6/19 had received 1 pr ior 
chemotherapy, 9/19 had received 2 prior chemotherapies and 4/19 
had received >2 prior chemotherapies. 5/19 had received a prior 
AHSCT. 17/19 were transplanted from a related donor and 2 of 
these were syngeneic pairs. 13/17 who had a related donor 
received a CD34-selected marrow. The 2 syngeneic transplants 
used either unmanipulated marrow or PBSC. The remaining 2 
related al lo-HSCT received umnanipulated marrow. The condi- 
t ioning regimen in 14/19 was VP-16 (60 
mg/kg)/melphalan(14Omg/m2)/TBI(500 [13/19] or 1200 
[l/19]cGy). The remainder eceived BU/CY (4/19) or CY/TBI 
(1/!9). 12/19 received 1.25 mg/kg ATG. 13/19 received only 
cyclosporin for GVHD prophylaxis while 4/19 received bot[a 
cyclosporin and methotrexate and no GVHD prophylaxis was 
given to the syngeneic recipients. The  median follow-up and 
range has been 4.3 (0 - 8.9) years. The median time and range to 
neutrophil (>0.5x109/L) and platelet (>20x109/L) engraftment 
was 17 (11 - 30) and 22 (8 168) days, respectively. Acute GVHD 
was seen in 4/19 patients. 3/4 had grade 2 - 3 GVHD. 5/19 had 
chronic GVHD. 5/19 developed CMV detected in the blood and 
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